Literature DB >> 2548911

Octreotide (SMS 201-995) in the treatment of metastatic glucagonoma: report of one case and review of the literature.

A Rosenbaum1, B Flourie, S Chagnon, M Blery, R Modigliani.   

Abstract

We report 1 patient with a necrolytic migratory erythema, a high plasma glucagon concentration and a metastatic pancreatic endocrine tumor who has now been treated effectively for 33 months with the somatostatin analogue octreotide (SMS 201-995) (400 micrograms/day). The results of SMS 201-995 in the treatment of glucagonoma syndrome are reviewed.

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2548911     DOI： 10.1159/000199835

Source DB:  PubMed          Journal:  Digestion        ISSN： 0012-2823            Impact factor:   3.216


  5 in total

Review 1.  Somatostatin analog therapy in treatment of gastrointestinal disorders and tumors.

Authors:  Wouter W de Herder; Steven W J Lamberts
Journal:  Endocrine       Date:  2003-04       Impact factor: 3.633

2.  [The question of surgical therapy for necrolytic migratory erythema, a cutaneous disease].

Authors:  R Siegel; R Linse; B Rau
Journal:  Chirurg       Date:  2006-06       Impact factor: 0.955

3.  Endocrine pancreatic tumors with glucagon hypersecretion: a retrospective study of 23 cases during 20 years.

Authors:  Henrik Kindmark; Anders Sundin; Dan Granberg; Kristina Dunder; Britt Skogseid; Eva Tiensuu Janson; Staffan Welin; Kjell Oberg; Barbro Eriksson
Journal:  Med Oncol       Date:  2007       Impact factor: 3.064

4.  The long-acting somatostatin analogue octreotide alleviates symptoms by reducing posttranslational conversion of prepro-glucagon to glucagon in a patient with malignant glucagonoma, but does not prevent tumor growth.

Authors:  F Jockenhövel; S Lederbogen; T Olbricht; H Schmidt-Gayk; E P Krenning; S W Lamberts; D Reinwein
Journal:  Clin Investig       Date:  1994-01

5.  Necrolytic migratory erythema associated with glucagonoma: a report of 2 cases.

Authors:  Renata Câmara Teixeira; Marcello Menta Simonsen Nico; Anelise Casillo Ghideti
Journal:  Clinics (Sao Paulo)       Date:  2008-04       Impact factor: 2.365
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.